1. Calvo-Rodriguez M, Kharitonova EK and Bacskai BJ: Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease. Cells 9: 2020.
2. Wisniewski T and Goñi F: Immunotherapy for Alzheimer's disease. Biochemical pharmacology 88: 499-507, 2014.
3. Imbimbo BP, Lombard J and Pomara N: Pathophysiology of Alzheimer's disease. Neuroimaging clinics of North America 15: 727-753, ix, 2005.
4. Kumar A, Singh A and Ekavali: A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological Reports 67: 195-203, 2015.
5. Selkoe DJ: Alzheimer's disease. Cold Spring Harbor perspectives in biology 3: 2011.
6. Götz J and Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nature reviews Neuroscience 9: 532-544, 2008.
7. Davies P and Maloney AJF: SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE. The Lancet 308: 1403, 1976.
8. Frost B, Jacks RL and Diamond MI: Propagation of Tau Misfolding from the Outside to the Inside of a Cell. Journal of Biological Chemistry 284: 12845-12852, 2009.
9. Hardy JA and Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science (New York, NY) 256: 184-185, 1992.
10. McGeer PL and Rogers J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42: 447-449, 1992.
11. Tarasoff-Conway JM, Carare RO, Osorio RS, et al: Clearance systems in the brain-implications for Alzheimer disease. Nature reviews Neurology 11: 457-470, 2015.
12. Salomone S, Caraci F, Leggio GM, Fedotova J and Drago F: New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British journal of clinical pharmacology 73: 504-517, 2012.
13. Bedse G, Romano A, Lavecchia AM, Cassano T and Gaetani S: The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. Journal of Alzheimer's disease : JAD 43: 1115-1136, 2015.
14. Van der Schyf CJ and Geldenhuys WJ: Multimodal drugs and their future for Alzheimer's and Parkinson's disease. In: International Review of Neurobiology. Vol 100. Youdim MBH and Douce P (eds). Academic Press, pp107-125, 2011.
15. Bilkei-Gorzo A: The endocannabinoid system in normal and pathological brain ageing. Philosophical Transactions of the Royal Society B: Biological Sciences 367: 3326-3341, 2012.
16. Germain N, Boichot E, Advenier C, Berdyshev EV and Lagente V: Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells. International immunopharmacology 2: 537-543, 2002.
17. Marsicano G, Moosmann B, Hermann H, Lutz B and Behl C: Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. Journal of neurochemistry 80: 448-456, 2002.
18. Esposito G, De Filippis D, Carnuccio R, Izzo AA and Iuvone T: The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. Journal of Molecular Medicine 84: 253-258, 2006.
19. Esposito G, Filippis DD, Maiuri M, Stefano D and Iuvone T: Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in#2-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-oB involvement. Neuroscience Letters 399: 91-95, 2006.
20. Harvey BS, Ohlsson KS, Mååg JLV, Musgrave IF and Smid SD: Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. NeuroToxicology 33: 138-146, 2012.
21. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M and Izzo AA: Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. Journal of neurochemistry 89: 134-141, 2004.
22. Janefjord E, Mååg JLV, Harvey BS and Smid SD: Cannabinoid Effects on β Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In Vitro. Cellular and Molecular Neurobiology 34: 31-42, 2014.
23. Martín-Moreno AM, Reigada D, Ramírez BG, et al: Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease. Molecular pharmacology 79: 964-973, 2011.
24. Scuderi C, Steardo L and Esposito G: Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement. Phytotherapy Research 28: 1007-1013, 2014.
25. Cheng D, Low JK, Logge W, Garner B and Karl T: Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice. Psychopharmacology 231: 3009-3017, 2014.
26. Cheng D, Spiro AS, Jenner AM, Garner B and Karl T: Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer's Disease Transgenic Mice. Journal of Alzheimer's Disease 42: 1383-1396, 2014.
27. Esposito G, Scuderi C, Savani C, et al: Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Br J Pharmacol 151: 1272-1279, 2007.
28. Esposito G, Scuderi C, Valenza M, et al: Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement. PLOS ONE 6: e28668, 2011.
29. Yiannopoulou KG and Papageorgiou SG: Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 6: 19-33, 2013